Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $2 | $3 |
| Operating Income | -$3 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$2 | -$2 | -$2 |
| Tax Expense | -$1 | -$0 | $0 | $2 |
| Net Income | $0 | -$2 | -$2 | -$4 |
| % Margin | – | – | – | – |
| EPS | 0.01 | -0.54 | -0.52 | -1.41 |
| % Growth | 101.9% | -3.8% | 63.1% | – |
| EPS Diluted | 0.01 | -0.54 | -0.52 | -1.41 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 3 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$2 | -$2 |
| % Margin | – | – | – | – |